(NewsDirect)
Adrian Mendes, the CEO of PerimeterMedical Imaging, joined Steve Darling from Proactive with news thatthe company has initiated an additional clinical trial site at theUniversity of Washington in the Fred Hutch Cancer Center.
Perimeter's clinical trial is amulti-center, randomized, two-arm pivotal study that evaluates theinvestigational Perimeter B-Series Optical Coherence Tomography (OCT)technology. This technology is combined with Perimeter'sproprietary ImgAssist AI software and is used during breastconservation surgeries.
The core ofthis innovative approach is the use of ultra-high-resolution,real-time, advanced imaging tools to examine excised tissues at thecellular level, providing crucial insights to surgeons.
Mendes emphasized the significance of thisadditional clinical trial site, as it plays a vital role in gatheringvaluable data generated during the study. This data will beinstrumental in supporting the commercialization of Perimeter'sB-Series technology.
Thecompany's ultimate goal is to transform cancer surgery byproviding advanced technology that not only improves patient outcomesbut also helps reduce healthcare costs.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.